Effect of Antisense Oligonucleotides on CD34+ Cells from Chronic Myeloid Leukemia von Pigneux, A., Mahon, E. X., Jazwiec, B., Pigeonnier, V., Rifqche, J., Reiffers, J.

Volltext

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial von Prey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., Kostrzewa, E., Quemeneur, T., Paul, C., Schaeverbeke, T., Seneschal, J., Solanilla, A., Sparsa, A., Bouchet, S., Lepreux, S., Mahon, F.-X., Chene, G., Taïeb, A.

Volltext

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network von Schäfer, Vivien, White, Helen E., Gerrard, Gareth, Möbius, Susanne, Saussele, Susanne, Franke, Georg-Nikolaus, Mahon, François-X., Talmaci, Rodica, Colomer, Dolors, Soverini, Simona, Machova Polakova, Katerina, Cross, Nicholas C. P., Hochhaus, Andreas, Ernst, Thomas

Volltext

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta von Apperley, Jane F, Gardembas, Martine, Melo, Junia V, Russell-Jones, Robin, Bain, Barbara J, Baxter, E. Joanna, Chase, Andrew, Chessells, Judith M, Colombat, Marie, Dearden, Claire E, Dimitrijevic, Sasa, Mahon, François-X, Marin, David, Nikolova, Zariana, Olavarria, Eduardo, Silberman, Sandra, Schultheis, Beate, Cross, Nicholas C.P, Goldman, John M

Volltext

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi( )-LMC... von NICOLINI, F. E, CORM, S, FACON, T, MAHON, F.-X, CAYUELA, J.-M, ROUSSELOT, P, MICHALLET, M, PREUDHOMME, C, GUILHOT, F, ROCHE-LESTIENNE, C, LE, Q.-H, SOREL, N, HAYETTE, S, BORIES, D, LEGUAY, T, ROY, L, GIRAUDIER, S, TULLIEZ, M

Volltext

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial von Saussele, Susanne, Richter, Johan, Guilhot, Joelle, Gruber, Franz X, Hjorth-Hansen, Henrik, Almeida, Antonio, Janssen, Jeroen J W M, Mayer, Jiri, Koskenvesa, Perttu, Panayiotidis, Panayiotis, Olsson-Strömberg, Ulla, Martinez-Lopez, Joaquin, Rousselot, Philippe, Vestergaard, Hanne, Ehrencrona, Hans, Kairisto, Veli, Machová Poláková, Katerina, Müller, Martin C, Mustjoki, Satu, Berger, Marc G, Fabarius, Alice, Hofmann, Wolf-Karsten, Hochhaus, Andreas, Pfirrmann, Markus, Mahon, Francois-Xavier, Ossenkoppele, Gert, Pagoni, Maria N., Söderlund, Stina, Escoffre-Barbe, Martine, Etienne, Gabriel, Dengler, Jolanta, Huguet, Francoise, von Bubnoff, Nikolas, Klamova, Hana, Faber, Edgar, Guilhot, Francois, Lotfi, Kourosh, Rea, Delphine, Brümmendorf, Tim H., de Greef, Gorgine E., Stenke, Leif, Nicolini, Franck E., Legros, Laurence, Burchert, Andreas, Voglova, Jaroslava, Charbonnier, Aude, Gyan, Emmanuel, Kunzmann, Volker, Westerweel, Peter E.

Volltext

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia von Ilander, M, Olsson-Strömberg, U, Schlums, H, Guilhot, J, Brück, O, Lähteenmäki, H, Kasanen, T, Koskenvesa, P, Söderlund, S, Höglund, M, Markevärn, B, Själander, A, Lotfi, K, Dreimane, A, Lübking, A, Holm, E, Björeman, M, Lehmann, S, Stenke, L, Ohm, L, Gedde-Dahl, T, Majeed, W, Ehrencrona, H, Koskela, S, Saussele, S, Mahon, F-X, Porkka, K, Hjorth-Hansen, H, Bryceson, Y T, Richter, J, Mustjoki, S

Volltext

Pharmacokinetic pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia von Cortes, J E, Egorin, M J, Guilhot, F, Molimard, M, Mahon, F-X

Volltext

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia von Preudhomme, Claude, Guilhot, François, Guilhot, Joëlle, Nicolini, Franck Emmanuel, Guerci-Bresler, Agnès, Rigal-Huguet, Françoise, Maloisel, Frederic, Coiteux, Valérie, Gardembas, Martine, Berthou, Christian, Vekhoff, Anne, Rea, Delphine, Jourdan, Eric, Allard, Christian, Delmer, Alain, Rousselot, Philippe, Legros, Laurence, Berger, Marc, Corm, Selim, Etienne, Gabriel, Roche-Lestienne, Catherine, Eclache, Virginie, Mahon, François-Xavier

Volltext

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders von Valent, P, Sotlar, K, Blatt, K, Hartmann, K, Reiter, A, Sadovnik, I, Sperr, W R, Bettelheim, P, Akin, C, Bauer, K, George, T I, Hadzijusufovic, E, Wolf, D, Gotlib, J, Mahon, F-X, Metcalfe, D D, Horny, H-P, Arock, M

Volltext

Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients von Fossard, Gaëlle, Blond, Emilie, Balsat, Marie, Morisset, Stéphane, Giraudier, Stéphane, Escoffre-Barbe, Martine, Labussière-Wallet, Hélène, Heiblig, Maël, Bert, Arthur, Etienne, Madeleine, Drai, Jocelyne, Sobh, Mohamad, Redonnet-Vernhet, Isabelle, Lega, Jean-Christophe, Mahon, François-Xavier, Etienne, Gabriel, Nicolini, Franck Emmanuel

Volltext

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase von Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G

Volltext

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia von Roche-Lestienne, C, Marceau, A, Labis, E, Nibourel, O, Coiteux, V, Guilhot, J, Legros, L, Nicolini, F, Rousselot, P, Gardembas, M, Helevaut, N, Frimat, C, Mahon, F-X, Guilhot, F, Preudhomme, C

Volltext

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France von Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.

Volltext

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI von Richter, Johan, Lübking, Anna, Söderlund, Stina, Lotfi, Kourosh, Markevärn, Berit, Själander, Anders, Stenke, Leif, Deneberg, Stefan, Ahlstrand, Erik, Myhr-Eriksson, Kristina, Panayiotidis, Panayiotis, Gedde-Dahl, Tobias, Žáčková, Daniela, Mayer, Jiří, Olsson-Strömberg, Ulla, Mahon, Francois-Xavier, Saussele, Susanne, Hjorth-Hansen, Henrik, Koskenvesa, Perttu

Volltext

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results von Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H

Volltext

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy von Etienne, Gabriel, Dulucq, Stéphanie, Nicolini, Franck-Emmanuel, Morisset, Stéphane, Fort, Marie-Pierre, Schmitt, Anna, Etienne, Madeleine, Hayette, Sandrine, Lippert, Eric, Bureau, Caroline, Tigaud, Isabelle, Adiko, Didier, Marit, Gérald, Reiffers, Josy, Mahon, François-Xavier

Volltext

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia von Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.

Volltext

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia von Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., O’Hare, Thomas

Volltext

Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders von Bonifazi, Francesca, de Vivo, Antonio, Rosti, Gianantonio, Guilhot, François, Guilhot, Joëlle, Trabacchi, Elena, Hehlmann, Rüdiger, Hochhaus, Andreas, Shepherd, Patricia C.A., Steegmann, Juan Luis, Kluin-Nelemans, Hanneke C., Thaler, Josef, Simonsson, Bengt, Louwagie, Andries, Reiffers, Josy, Mahon, François Xavier, Montefusco, Enrico, Alimena, Giuliana, Hasford, Joerg, Richards, Sue, Saglio, Giuseppe, Testoni, Nicoletta, Martinelli, Giovanni, Tura, Sante, Baccarani, Michele, for the European Study Group on Interferon in Chronic Myeloid Leukemia

Volltext